Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 2/20 | 0.55 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.55 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | AMY2A | P04746 | 3/20 | 0.48 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SELL | P14151 | 2/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.43 |
| ▸ | SELE | P16581 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357803 | 1.00 | LGALS3 (0.55) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL30442354 | 1.00 | LGALS3 (0.55) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL14268511 | 1.00 | LGALS3 (0.55) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL11505202 | 1.00 | LGALS3 (0.55) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL12203873 | 1.00 | LGALS3 (0.55) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL10086040 | 1.00 | LGALS3 (0.55) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL21128354 | 1.00 | LGALS3 (0.55) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL20516505 | 1.00 | LGALS3 (0.55) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL20516519 | 1.00 | LGALS3 (0.55) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL29353032 | 1.00 | LGALS3 (0.55) | LGALS3LGALS8LGALS4MAPK1AMY2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12634422-B2 | Information processing device, information processing method, and program for calculating a crosstalk parameter set | Sony Group Corporation (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20250168310-A1 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, AND PROGRAM THEREFOR | Sony Group Corporation (JP) | 2025-05-22 | — | — | US | disclosed |
| US-20250001009-A1 | THERAPY FOR PROGRAMMED CELL DEATH IN A SUBJECT TRANSPLANTED WITH A DONOR LIVER CARRYING THE PNPLA3 RS738409:G VARIANT | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-01-02 | — | — | US | disclosed |
| EP-4478703-A1 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, AND PROGRAM | Sony Group Corporation (JP) | 2024-12-18 | — | — | EP | disclosed |
| US-12070504-B1 | Compounds and methods for altering cyto-states of cells that express c-type lectin receptors | Physis International LLC (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2023152822-A1 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, AND PROGRAM | ソニーグループ株式会社 | 2023-08-17 | — | — | WO | disclosed |
| WO-2023092134-A1 | THERAPY FOR PROGRAMMED CELL DEATH IN SUBJECTS TRANSPLANTED WITH A DONOR LIVER CARRYING THE PNPLA3 RS738409:G VARIANT | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3959751-A1 | HIGH BRIGHTNESS LEDS WITH NON-SPECULAR NANOSTRUCTURED THIN FILM REFLECTORS | Lumileds LLC (US) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12070504-B1 | Compounds and methods for altering cyto-states of cells that express c-type lectin receptors | NTSR1, LY96, GALR1 | LGALS3 22/4885LGALS8 70/4885LGALS4 6/4885 |
| US-12634422-B2 | Information processing device, information processing method, and program for calculating a crosstalk parameter set | TGFB2, TSNAX, CTNND1 | LGALS3 202/4885LGALS8 342/4885LGALS4 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.